These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19487913)

  • 21. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
    Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of head and neck cancers: issues for clinical pharmacists.
    Scarpace SL; Brodzik FA; Mehdi S; Belgam R
    Pharmacotherapy; 2009 May; 29(5):578-92. PubMed ID: 19397465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnostic image; a man with severe radiation dermatitis].
    Janssens GO; van Herpen CM
    Ned Tijdschr Geneeskd; 2009; 153():B413. PubMed ID: 19785863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials.
    Hallqvist A; Bergman B; Nyman J
    Radiother Oncol; 2012 Jul; 104(1):39-44. PubMed ID: 22727262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
    Bernier J; Schneider D
    Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy related skin toxicity (RAREST-01): Mepitel® film versus standard care in patients with locally advanced head-and-neck cancer.
    Narvaez C; Doemer C; Idel C; Setter C; Olbrich D; Ujmajuridze Z; Carl JH; Rades D
    BMC Cancer; 2018 Feb; 18(1):197. PubMed ID: 29454311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Bourhis J; Lefebvre JL; Vermorken JB
    Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.
    Pryor DI; Porceddu SV; Burmeister BH; Guminski A; Thomson DB; Shepherdson K; Poulsen M
    Radiother Oncol; 2009 Feb; 90(2):172-6. PubMed ID: 18976827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer.
    Chitapanarux I; Lorvidhaya V; Tharavichitkul E; Mayurasakorn S; Sittitrai P; Pattarasakulchai T; Tananuwat R; Srivanitchapoom C
    Auris Nasus Larynx; 2011 Feb; 38(1):108-13. PubMed ID: 20591592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.
    Selzer E; Liederer S; Lemaire C; Kren G; Radonjic D; Kornek G; Knocke T; Pötter R; Bachtiary B
    Strahlenther Onkol; 2011 Jun; 187(6):373-7. PubMed ID: 21603990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
    Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
    BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer.
    Kim B; Dillman RO; Chen P; Hafer R; Cox C; Barth N; Carroll RM; VanderMolen L; Nguyen M; Huang J; Minion A; Plunkett M; Mackintosh R
    Am J Otolaryngol; 2012; 33(1):93-7. PubMed ID: 21524816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.
    Yokota T; Zenda S; Ota I; Yamazaki T; Yamaguchi T; Ogawa T; Tachibana H; Toshiyasu T; Homma A; Miyaji T; Mashiko T; Hamauchi S; Tominaga K; Ishii S; Otani Y; Orito N; Uchitomi Y
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):794-803. PubMed ID: 34102298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A population-based study of therapy and survival for patients with head and neck cancer treated in the community.
    Dansky Ullmann C; Harlan LC; Shavers VL; Stevens JL
    Cancer; 2012 Sep; 118(18):4452-61. PubMed ID: 22252676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of HMB/Arg/Gln on the prevention of radiation dermatitis in head and neck cancer patients treated with concurrent chemoradiotherapy.
    Imai T; Matsuura K; Asada Y; Sagai S; Katagiri K; Ishida E; Saito D; Sadayasu R; Wada H; Saijo S
    Jpn J Clin Oncol; 2014 May; 44(5):422-7. PubMed ID: 24688085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
    Choe KS; Haraf DJ; Solanki A; Cohen EE; Seiwert TY; Stenson KM; Blair EA; Portugal L; Villaflor VM; Witt ME; Vokes EE; Salama JK
    Cancer; 2011 Oct; 117(20):4671-8. PubMed ID: 21671479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
    Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH
    Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.